ELP6

Across TCGA pan-cancer cohorts, ELP6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ELP6 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ELP6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELP6 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

GBM, PDAC, and CCRCC are the cancer types where ELP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.234	0.587	.003	31	view →
PDAC	DFS	Median	III,IV	0.494	0.249	.015	19	view →
CCRCC	DFS	Tertile	IV	0.188	0.948	.024	13	view →
LUAD	OS	Median	II,III,IV	0.463	0.756	.047	2	view →
LSCC	DFS	Median	All	0.905	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ELP6–GBM (DFS)

Open the GBM breakdown →